Abstract
Osteosarcoma is the most common type of primary bone tumor in adolescents and young adults. The dysregulation of cell cycle control and cell division often results in the aberrant growth of osteosarcoma cells. The primary proteins involved in cell cycle control and cell division include checkpoint kinases (CHKs), cyclin-dependent kinases (CDKs), polo-like kinases (PLKs) and aurora kinases (AURKs). In recent years, a large number of these protein kinase inhibitors have been identified in osteosarcoma. In this review, we highlight the current drugs being developed to target these protein kinases in osteosarcoma.
Keywords: Checkpoint kinase inhibitors, cyclin-dependent kinase inhibitors, polo-like kinase inhibitors, aurora kinase inhibitors, cell cycle, osteosarcoma.
Current Pharmaceutical Design
Title:Cell Cycle Kinases in Osteosarcoma: Potential for Therapeutic Intervention
Volume: 22 Issue: 31
Author(s): Li Cheng, Chongchong Wang and Juehua Jing
Affiliation:
Keywords: Checkpoint kinase inhibitors, cyclin-dependent kinase inhibitors, polo-like kinase inhibitors, aurora kinase inhibitors, cell cycle, osteosarcoma.
Abstract: Osteosarcoma is the most common type of primary bone tumor in adolescents and young adults. The dysregulation of cell cycle control and cell division often results in the aberrant growth of osteosarcoma cells. The primary proteins involved in cell cycle control and cell division include checkpoint kinases (CHKs), cyclin-dependent kinases (CDKs), polo-like kinases (PLKs) and aurora kinases (AURKs). In recent years, a large number of these protein kinase inhibitors have been identified in osteosarcoma. In this review, we highlight the current drugs being developed to target these protein kinases in osteosarcoma.
Export Options
About this article
Cite this article as:
Cheng Li, Wang Chongchong and Jing Juehua, Cell Cycle Kinases in Osteosarcoma: Potential for Therapeutic Intervention, Current Pharmaceutical Design 2016; 22 (31) . https://dx.doi.org/10.2174/1381612822666160512151028
DOI https://dx.doi.org/10.2174/1381612822666160512151028 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Stathmin, Interacting with Nf-κB, Promotes Tumor Growth and Predicts Poor Prognosis of Pancreatic Cancer
Current Molecular Medicine A Natural Membrane Vesicle Exosome-based Sinomenine Delivery Platform for Hepatic Carcinoma Therapy
Current Topics in Medicinal Chemistry Impact of Epigenetic Dietary Components on Cancer through Histone Modifications
Current Medicinal Chemistry Systematic Evaluation of Drug-Loaded Hydrogels for Application in Osteosarcoma Treatment
Current Pharmaceutical Biotechnology Paclitaxel Loaded Nanoliposomes in Thermosensitive Hydrogel: A Dual Approach for Sustained and Localized Delivery
Anti-Cancer Agents in Medicinal Chemistry Cucurbitacin IIb from Ibervillea sonorae Induces Apoptosis and Cell Cycle Arrest via STAT3 Inhibition
Anti-Cancer Agents in Medicinal Chemistry 15,16-dihydrotanshinone I Induces Apoptosis and Inhibits the Proliferation, Migration of Human Osteosarcoma Cell Line 143B in vitro
Anti-Cancer Agents in Medicinal Chemistry Triterpenoid Saponins from Two Panax japonicus Varietals Used in Tujia Ethnomedicine
Current Traditional Medicine The Vitamin D/CYP24A1 Story in Cancer
Anti-Cancer Agents in Medicinal Chemistry Targeting mTOR Pathways in Human Malignancies
Current Pharmaceutical Design P53 Family: At the Crossroads in Cancer Therapy
Current Medicinal Chemistry Enhanced Pro-Apoptotic Effect of Tetrandrine Loaded Nanoparticles Against Osteosarcoma Cells
Current Drug Delivery Human Apurinic/Apyrimidinic Endonuclease (APE1): An Emerging Anti-Cancer Biomarker
Recent Patents on Biomarkers Peptides to Target Tumor Vasculature and Lymphatics for Improved Anti-Angiogenesis Therapy
Current Cancer Drug Targets Redox-active and Redox-silent Compounds: Synergistic Therapeutics in Cancer
Current Medicinal Chemistry Resveratrol in Medicinal Chemistry: A Critical Review of its Pharmacokinetics, Drug-Delivery, and Membrane Interactions
Current Medicinal Chemistry miR-375 Inhibits the Proliferation, Migration and Invasion of Esophageal Squamous Cell Carcinoma by Targeting XPR1
Current Gene Therapy Enzyme-responsive Nanoparticles for Anticancer Drug Delivery
Current Nanoscience Substrates for Improved Live-Cell Fluorescence Labeling of SNAP-tag
Current Pharmaceutical Design Application of Liposomes in Cancer Therapy: An Assessment of the Advancement of Technology Through Patent Documents
Recent Patents on Nanotechnology